Yesterday it was reported that the President & CEO of Nektar Therapeutics (NKTR), Howard Robin, exercised options to buy 30,000 NKTR shares at $16.31 a share, for a total transaction value of $489.3K.
Following this transaction Howard Robin’s holding in the company was increased by 10.59% to a total of $5.41 million. Following Howard Robin’s last NKTR Buy transaction on February 17, 2017, the stock climbed by 4.2%.
See today’s analyst top recommended stocks >>
The company has a one-year high of $69.76 and a one-year low of $16.56.
Six different firms, including BMO Capital and BTIG, currently also have a Buy rating on the stock.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The company focuses on the therapies for cancer, autoimmune disease, and chronic pain. It operates through the United States and Europe geographical segments.
